cilofexor: Clinical Trials

4 trials of cilofexor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow cilofexor: new trials by email Literature Review of cilofexor trials Research Report on cilofexor

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA - Nonalcoholic Steatohepatitis
Phase 2CompletedGilead Sciences4572021-08-092025-11-26
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Semaglutide, Firsocostat, Cilofexor - Nonalcoholic Steatohepatitis
Phase 2CompletedGilead Sciences1092019-07-292021-07-15
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis
Phase 2TerminatedGilead Sciences712016-12-012020-09-22
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
Cilofexor, Placebo to match cilofexor - Primary Sclerosing Cholangitis
Phase 2CompletedGilead Sciences522016-11-292021-06-07

Conditions studied

Non-alcoholic Fatty Liver Disease (2)  ·  Cholangitis, Sclerosing (1)  ·  Liver Cirrhosis, Biliary (1)

Sponsors

Gilead Sciences (4)

Countries

United States (4)  ·  Canada (3)  ·  Austria (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  France (1)  ·  Japan (1)  ·  Puerto Rico (1)  ·  Spain (1)

Results publications

PMID 30661255, PMID 35439567

NIH funding

2016 (2)